• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Genmab A/S

< Previous 1 2 3 Next >
EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
September 25, 2023
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
September 04, 2023
From Genmab A/S
Via Business Wire
Tickers GMAB SGEN
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
September 04, 2023
From Genmab A/S
Via GlobeNewswire
Genmab Announces Financial Results for the First Half of 2023
August 03, 2023
From Genmab A/S
Via GlobeNewswire
Genmab Updates 2023 Financial Guidance
July 27, 2023
From Genmab A/S
Via GlobeNewswire
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
July 21, 2023
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
July 21, 2023
From Genmab A/S
Via GlobeNewswire
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023
July 20, 2023
From Genmab A/S
Via GlobeNewswire
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
June 27, 2023
From Genmab A/S
Via GlobeNewswire
Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
May 25, 2023
From Genmab A/S
Via Business Wire
Tickers GMAB
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
May 19, 2023
From Genmab A/S
Via Business Wire
Tickers GMAB
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
May 19, 2023
From Genmab A/S
Via GlobeNewswire
Genmab Announces Financial Results for the First Quarter of 2023
May 10, 2023
From Genmab A/S
Via GlobeNewswire
Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen
April 24, 2023
From Genmab A/S
Via GlobeNewswire
Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen
April 20, 2023
From Genmab A/S
Via GlobeNewswire
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023
April 18, 2023
From Genmab A/S
Via GlobeNewswire
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
April 17, 2023
From Genmab A/S
Via GlobeNewswire
Genmab Announces Initiation of Share Buy-Back Program
February 22, 2023
From Genmab A/S
Via GlobeNewswire
Genmab Publishes 2022 Annual Report
February 22, 2023
From Genmab A/S
Via GlobeNewswire
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022
January 24, 2023
From Genmab A/S
Via GlobeNewswire
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
December 21, 2022
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting
December 11, 2022
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces Financial Results for the First Nine Months of 2022
November 09, 2022
From Genmab A/S
Via GlobeNewswire
Genmab Improves Its 2022 Financial Guidance
November 03, 2022
From Genmab A/S
Via GlobeNewswire
Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)
November 03, 2022
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)
October 28, 2022
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2022
October 18, 2022
From Genmab A/S
Via GlobeNewswire
Major Shareholder Announcement
October 05, 2022
From Genmab A/S
Via GlobeNewswire
Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
August 05, 2022
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
July 18, 2022
From Genmab A/S
Via Business Wire
Tickers ABBV GMAB
< Previous 1 2 3 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap